These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37647596)

  • 1. Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90.
    Feraco AM; Zhou Y; Zheng Y; Marks LJ; Friedmann A; Weinstein HJ; Link MP; Flerlage JE
    Blood Adv; 2023 Nov; 7(21):6665-6667. PubMed ID: 37647596
    [No Abstract]   [Full Text] [Related]  

  • 2. [New treatment options for patients with Non-Hodgkin and Hodgkin lymphoma: changing treatment standards and improvements in prognosis].
    Bücklein V
    MMW Fortschr Med; 2023 Jan; 165(1):48-51. PubMed ID: 36648674
    [No Abstract]   [Full Text] [Related]  

  • 3. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.
    Schot BW; Zijlstra JM; Sluiter WJ; van Imhoff GW; Pruim J; Vaalburg W; Vellenga E
    Blood; 2007 Jan; 109(2):486-91. PubMed ID: 17003382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The broader prospects for bispecifics in Hodgkin lymphoma.
    Chohan KL; Ansell SM
    Leuk Lymphoma; 2022 Aug; 63(8):1777-1779. PubMed ID: 35920699
    [No Abstract]   [Full Text] [Related]  

  • 5. Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors.
    Vassilakopoulos TP; Kravvariti E; Panitsas F; Angelopoulou MK; Liaskas A; Kontopidou FN; Yiakoumis X; Variami E; Dimopoulou MN; Siakantaris MP; Asimakopoulos JV; Arapaki M; Dimou M; Diamantopoulos P; Sachanas S; Chatzidimitriou C; Belia M; Konstantinou E; Boutsikas G; Petevi K; Kanellopoulos A; Kokoris S; Kyrtsonis MC; Viniou NA; Lakiotaki E; Tsourouflis G; Korkolopoulou P; Konstantopoulos K; Panayiotidis P; Pangalis GA
    Blood Cancer J; 2022 Jul; 12(7):102. PubMed ID: 35790712
    [No Abstract]   [Full Text] [Related]  

  • 6. Adolescents with Hodgkin lymphoma: a great treatment challenge.
    Mauz-Körholz C
    Lancet Haematol; 2022 Jan; 9(1):e5-e6. PubMed ID: 34971583
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hodgkin lymphoma and non-Hodgkin lymphoma].
    Yamaguchi M
    Rinsho Ketsueki; 2013 Jan; 54(1):81-8. PubMed ID: 23391651
    [No Abstract]   [Full Text] [Related]  

  • 8. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies.
    Mottok A; Steidl C
    Blood; 2018 Apr; 131(15):1654-1665. PubMed ID: 29500175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Composite lymphoma].
    Lloveras N; Pleusa E; Batlle M; Mate JL
    Med Clin (Barc); 2003 Sep; 121(8):319. PubMed ID: 14499097
    [No Abstract]   [Full Text] [Related]  

  • 10. Bone marrow involvement by hodgkin and non-hodgkin lymphomas.
    Zhang QY; Foucar K
    Hematol Oncol Clin North Am; 2009 Aug; 23(4):873-902. PubMed ID: 19577173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma.
    Re A; Casari S; Cattaneo C; Facchetti F; Cadeo G; Carosi G; Rossi G
    Cancer; 2001 Dec; 92(11):2739-45. PubMed ID: 11753946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?
    Specht L
    Curr Treat Options Oncol; 2016 Jan; 17(1):4. PubMed ID: 26739151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of some inflammatory markers in patients with lymphoma.
    Hamed Anber N; El-Sebaie AH; Darwish NHE; Mousa SA; Shamaa SS
    Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30814315
    [No Abstract]   [Full Text] [Related]  

  • 14. Nodular lymphocyte-predominant Hodgkin lymphoma.
    Savage KJ; Mottok A; Fanale M
    Semin Hematol; 2016 Jul; 53(3):190-202. PubMed ID: 27496311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-associated lymphoma.
    Kaplan LD
    AIDS Clin Rev; 1993-1994; ():145-66. PubMed ID: 8217897
    [No Abstract]   [Full Text] [Related]  

  • 16. Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab.
    Stuver R; Vardhana SA; Bedmutha A; Chan KK; Mirtcheva-Trocheva R; Nosov A; Schöder H; Moskowitz A
    Leuk Lymphoma; 2023 Dec; 64(14):2351-2353. PubMed ID: 37794809
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features.
    Zibara V; Sen F; Scordo M; Falchi L
    Leuk Lymphoma; 2022 Dec; 63(13):3241-3244. PubMed ID: 36120859
    [No Abstract]   [Full Text] [Related]  

  • 18. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
    Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
    Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphomas.
    Longo DL; Devita VT
    Cancer Chemother Biol Response Modif; 1991; 12():347-93. PubMed ID: 1931450
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinically relevant prognostic factors in malignant lymphoma].
    Engelhard M; Löffler M
    Internist (Berl); 1993 Feb; 34(2):127-31. PubMed ID: 8454425
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.